MRI-derived tumor burden and growth rate as translational biomarkers: Head-to-head comparison with RECIST and ctDNA in tebentafusp-treated metastatic uveal melanoma.
Toulsie Ramtohul(Université Paris Sciences et Lettres), Manuel Rodrigues(Institut Curie), Aurore Rampanou(Université Paris Sciences et Lettres), Nathalie Cassoux(Institut Curie), Léah Mailly-Giacchetti(Inserm), R. Sanchez(Institut Curie), Vincent Servois(Institut Curie), Sophie Piperno‐Neumann(Institut Curie), Xavier-Louis Jasawant(Université Paris Sciences et Lettres), José Luis Sandoval(Université Paris Sciences et Lettres), Shufang Renault(Institut Curie), Marc-Henri Stern(Institut Curie), Pascale Mariani(Institut Curie), Gaëlle Pierron(Institut Curie)
Cited by 0
Related Papers
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
|New England Journal of Medicine|2021|869
Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|751
Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRCI) ocular melanoma study
|Annals of Oncology|2019|282
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)
|Journal of Clinical Oncology|2018|274